These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33001202)

  • 41. Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial.
    Zeymer U; Montalescot G; Ardissino D; Bolognese L; Clemmensen P; Collet JP; Lopez-Sendon J; Widimsky P
    Eur Heart J Acute Cardiovasc Care; 2016 Jun; 5(3):282-8. PubMed ID: 25921481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
    Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.
    Zeymer U; Widimsky P; Danchin N; Lettino M; Bardaji A; Barrabes JA; Cequier A; Claeys MJ; De Luca L; Dörler J; Erlinge D; Erne P; Goldstein P; Koul SM; Lemesle G; Lüscher TF; Matter CM; Montalescot G; Radovanovic D; Sendón JL; Tousek P; Weidinger F; Weston CF; Zaman A; Andell P; Li J; Jukema JW;
    Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):229-43. PubMed ID: 27533946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Invasive Management Strategies and Antithrombotic Treatments in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome in China: Findings From the Improving CCC Project (Care for Cardiovascular Disease in China).
    Yang Q; Wang Y; Liu J; Liu J; Hao Y; Smith SC; Huo Y; Fonarow GC; Ma C; Ge J; Taubert KA; Morgan L; Guo Y; Wang W; Zhou Y; Zhao D;
    Circ Cardiovasc Interv; 2017 Jun; 10(6):. PubMed ID: 28606999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI.
    Pollack CV; Peacock WF; Bhandary DD; Silber SH; Bhalla N; Rao SV; Diercks DB; Frost A; Bangalore S; Heitner JF; Johnson C; DeRita R; Khan ND
    Crit Pathw Cardiol; 2020 Dec; 19(4):166-172. PubMed ID: 32947379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction.
    Yudi MB; Farouque O; Andrianopoulos N; Ajani AE; Brennan A; Lefkovits J; Reid CM; Chan W; Duffy SJ; Clark DJ;
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):E98-E105. PubMed ID: 28963757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively.
    Almendro-Delia M; Gonzalez-Torres L; Garcia-Alcantara Á; Reina-Toral A; Arboleda Sánchez JA; Rodríguez Yañez JC; Hidalgo-Urbano R; García Rubira JC;
    Am J Cardiol; 2015 Apr; 115(8):1019-26. PubMed ID: 25728644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. P2Y12 Receptor Antagonists: Which One to Choose? A Systematic Review and Meta-Analysis.
    Briasoulis A; Telila T; Palla M; Siasos G; Tousoulis D
    Curr Pharm Des; 2016; 22(29):4568-4576. PubMed ID: 27290917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Gach O; Nyssen A; Pirlet C; Magne J; Oury C; Lancellotti P
    J Cardiovasc Med (Hagerstown); 2018 May; 19(5):234-239. PubMed ID: 29528868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
    Bavishi C; Panwar S; Messerli FH; Bangalore S
    Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
    Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E;
    J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
    Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS
    Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.
    Komosa A; Lesiak M; Krasiński Z; Grygier M; Siniawski A; Skorupski W; Olasińska-Wiśniewska A; Pyda M; Araszkiewicz A; Mitkowski P; Grajek S; Mularek-Kubzdela T; Hengstenberg C; Siller-Matula JM
    Thromb Haemost; 2019 Jun; 119(6):1000-1020. PubMed ID: 30919382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.